We started up our protein–protein interaction technology development activities in 2006, our research activities in 2008, and from 2018, we are also a research service provider.
We are specialized in developing yeast two-hybrid system assays that can be used to attempt to confirm protein–protein interactions (PPIs) and to map protein–protein interaction domains (PPIDs). From PPID information candidate peptide protein–protein interaction inhibitors can be derived. Short linear peptides with PPI inhibitory activity have many applications in research and using them can reveal molecular mechanisms and provide new insights, what can lead to the development of new medicine.
In 2006, the company was founded by Fred Penninkhof, who received his PhD from the Erasmus University in Rotterdam in 2005.